Treatment of symptomatic adenomyosis with the levonorgestrel‐releasing intrauterine system

Lei Li, Jinhua Leng, Shuangzheng Jia, Jinghe Lang
International Journal of Gynecology & Obstetrics · 2019 · vol. 146(3) , pp. 357–363 · doi:10.1002/ijgo.12887 · PMID:31194884 · W2951839410
article OA: closed CC0 ⤵ 33 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Long-term use of the levonorgestrel-releasing intrauterine system significantly improved pain, bleeding, uterine volume, and CA125 levels in women with symptomatic adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To determine the long-term effects of using the levonorgestrel-releasing intrauterine system (LNG-IUS) to treat symptomatic adenomyosis. METHOD: A prospective longitudinal study was conducted among 1100 women who received the LNG-IUS at a tertiary teaching hospital in China between December 10, 2006, and December 24, 2014. All participants had symptomatic adenomyosis (visual analogue scale [VAS] ≥7 and/or pictorial blood loss assessment chart [PBAC] score >100) diagnosed by transvaginal sonography. Follow-up was at 3, 6, 12, 24, 36, 48, and 60 months after LNG-IUS placement. The primary outcome was symptom relief. Secondary outcomes included LNG-IUS retention status; changes in uterine volume; serum levels of cancer antigen 125 (CA125); menstruation pattern; and adverse events. RESULTS: In all, 374 (33.7%) participants completed 60 months of LNG-IUS treatment. The VAS, verbal rating scale, PBAC score, hemoglobin level, uterine volume, and serum CA125 level all showed marked improvements at this time point when compared with baseline (P<0.05 for all comparisons). The cumulative retention rate of LNG-IUS was 56.2%. Changes in menstruation pattern at 60 months included amenorrhea (n=97, 25.9%) and shortened periods (n=82, 21.9%). The incidence of adverse events was <10% and not considered notable. CONCLUSIONS: Long-term use of LNG-IUS was effective and acceptable for the treatment of symptomatic adenomyosis. Registered at clinicaltrials.gov (NCT03027648).

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Intrauterine Devices, Medicated Levonorgestrel Adenomyosis Adenomyosis Adult CA-125 Antigen CA-125 Antigen China Female Humans Levonorgestrel Longitudinal Studies Menstruation Menstruation Middle Aged Prospective Studies Treatment Outcome Ultrasonography Visual Analog Scale

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (25)

Cited by (34)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:22:41.077124+00:00
License: CC0 · commercial use OK